

# SLAMS 2013



## Efficacy and Safety of Linear Focused Shockwaves for Erectile Dysfunction (RENOVA) – A Second Generation Technology

Reisman, Y<sup>1</sup>; Hind, A<sup>2</sup>; Varaneckas, A<sup>3</sup>; Motil, I<sup>4</sup>

<sup>1</sup>Men's Health Clinic, Bovenij Hospital, Amsterdam, The Netherlands, <sup>2</sup>Urology and Andrology Center, Red Crescent Hospital (RCH), Ramallah, Palestine, <sup>3</sup>Amber Clinic, Klaipėda, Lithuania, <sup>4</sup>Uroclinic Brno, Brno, Czech Republic

### Introduction:

Recent studies have demonstrated that low intensity shockwaves have a therapeutic effect on ED of vascular origin.

### Objective:

The present study was aimed to assess the efficacy and safety of a dedicated shockwave device, Renova, which was designed to achieve substantially superior organ coverage.

### Material and Methods:

52 patients with mild to severe ED were treated by Renova as part of a multi-center, open-label, prospective pilot study, conducted at 4 sites. Patients underwent 4 weekly treatment sessions by a Renova that generates line focused shockwaves. Patients' erectile function was assessed by the IIEF-EF, SEP and GAQ questionnaires at baseline and at 1 and 3 months post treatment. Success was defined as an increase of IIEF-EF score from baseline to the second follow up according to the severity of the symptoms at baseline.

### Results:

The average IIEF-EF greatly increased from 14.7 at baseline to 21.4 at 1 month and 3 months post treatment. Out of 52 patients, 41 (79%) had a successful treatment. No adverse events were reported during the treatment and the follow-up duration. Main outcomes are presented in the following table:

Age	Baseline IIEF-EF	Improvement in IIEF-EF	P value	% Success
57.2 ± 10.1	14.7 ± 4.9	6.8	<0.0001	78.8%

### Conclusions:

The results of this study indicate success of the second generation technology for treating ED with linear low-intensity shockwaves. Initial follow up data demonstrate a therapeutic success in almost 80% of patients. No side effects have been recorded, demonstrating the suitability of this treatment in an office setting.

*The above paper abstract was delivered on the 12<sup>th</sup> Congress of the Latin American Society for Sexual Medicine on August 29, 2013, Cancun, Mexico.*